Oridion Systems Ltd : Oridion will Present at the J.P. Morgan Healthcare Conference

News Release Oridion will Present at the J.P. Morgan Healthcare Conference

Jerusalem/Needham - January 4, 2012 - Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN), the creator of the Integrated Pulmonary Index™, one of the Smart Capnography™ family of decision- support solutions, today announced that its management is scheduled to present the Company at the
30th Annual J.P. Morgan Healthcare Conference on January 11, 2012 at 07:30 a.m. (Pacific Time). The conference will be held at the Westin St. Francis Hotel in San Francisco/CA.
Alan Adler, Chairman and CEO of Oridion said: "We are delighted that we have been invited to present at this large and prestigious investment symposium."
The presentation that will be used during the Conference will become available on January 11, 2012 on the Company website www.oridion.com- section Investor Relations.

For further information please contact

Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
e-mail [e-mail] website http://www.oridion.com phone [phone]
address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

Upcoming event

February 27, 2012 Results 4th Quarter / Fiscal Year 2011

About Oridion

Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in Israel and the United
States.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward- looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology; resolution of the final nature of the recall; future

actions of the FDA with respect to the Company's implementation of the recall; future actions of the FDA or any other regulatory body or government authority that could delay, limit or suspend product development, manufacturing or sale or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities; product quality or patient safety issues.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

2